Long-Term Results of Ewing’s Sarcoma—In a Single Institution


Purpose: This study analyzed oncological and functional outcomes of treatment for Ewing’s sarcoma, as well as its significant risk factors through long-term follow up. Objective and Method: Between September 1990 and April 2009, 20 cases that were diagnosed and treated as Ewing’s sarcoma in Kosin University Gospel Hospital were entered onto the study. Mean follow-up period was 45.4 (12 - 108) months. There were 7 cases of male and 13 cases of female, and mean age was 19.9 (5 - 48) years old. Retrospective review was done about treatment outcomes, complications, and significant risk factors. Results: In terms of oncologic results, there were 9 cases of CDF (continuous disease free), 1 case of NED (no evidence of disease), 4 cases of AWD (alive with disease), 5 cases of DOD (dead of disease), and 1 case of DWOD (dead with other disease). Five-year overall survival rate of all the patients was 70.0% and event-free survival rate was 50.0%. The mean MSTS (Musculoskeletal Tumor Society) score was 15.9 (53%) points at last follow-up. Among prognostic factors of age at diagnosis, Enneking stage, size of tumor, site of primary lesion, and distant metastasis, 5-year survival rate of groups without metastasis were 90.9%, nevertheless 44.4% in other group with the metastasis showing statistical significance (p = 0.020). Postoperative complications were 3 cases of infection, each 2 cases of ankylosis and metal failure, and each 1 case of leg length discrepancy, periprosthetic fracture, and local recurrence. Conclusion: Five-year survival rate of this study was similar to that of multicenter studies in America and Europe. Among the prognostic factors, distant metastasis was proven to be most significant. Enneking stage, size of tumor and site of primary lesion are also important and could be statistically significant if with more cases.

Share and Cite:

J. Kim, T. Kim and S. Chung, "Long-Term Results of Ewing’s Sarcoma—In a Single Institution," Journal of Cancer Therapy, Vol. 4 No. 1, 2013, pp. 323-330. doi: 10.4236/jct.2013.41039.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Y. Iwamoto, “Diagnosis and Treatment of Ewing’s Sarcoma,” Japanese Journal of Clinical Oncology, Vol. 37, No. 2, 2007, pp. 79-89. doi:10.1093/jjco/hyl142
[2] W. F. Ennecking, W. K. Dunham, M. C. Gebhardt, M. Malawer and D. J. Prichard, “A System for the Evaluation of Reconstructive Procedures after Surgical Treatment of Tumors of the Musculoskeletal System,” Clinical Orthopaedics and Related Research, Vol. 286, 1993, pp. 241-246.
[3] E. L. Kaplan and R. Meier, “Nonparametric Estimation from Incomplete Observation,” Journal of the American Statistical Association, Vol. 53, No. 282, 1958, pp. 457-481. doi:10.1080/01621459.1958.10501452
[4] S. Laskar, I. Mallick, T. Gupta and M. A. Muckaden, “Post-Operative Radiotherapy for Ewing Sarcoma: When, How and How Much?” Pediatric Blood & Cancer, Vol. 51, No. 5, 2008, pp. 575-580. doi:10.1002/pbc.21657
[5] D. J. Indelicato, S. R. Keole, A. H. Shahlaee, W. Shi, C. G. Morris and R. B. Marcus Jr., “Definitive Radiotherapy for Ewing Tumors of Extremities and Pelvis: Long-Term Disease Control, Limb Function, and Treatment Toxicity,” International Journal of Radiation Oncology, Biology and Physics, Vol. 72, No. 3, 2008, pp. 871-877. doi:10.1016/j.ijrobp.2008.02.023
[6] S. Donaldson, “Ewing Sarcoma: Radiation Dose and Target Volume,” Pediatric Blood & Cancer, Vol. 42, No. 5, 2004, pp. 471-476. doi:10.1002/pbc.10472
[7] M. Bernstein, H. Kovar, M. Paulussen, et al., “Ewing’s Sarcoma Family of Tumors: Current Management,” The Oncologist, Vol. 11, No. 5, 2006, pp. 503-519.
[8] B. Padhye and G. McCowage, “Chemotherapy Regimens in Newly Diagnosed and Recurrent Ewing Sarcoma in Children and Young Adults,” Cancer Forums, Vol. 34, No. 3, 2010, pp. 1-7.
[9] S. A. Khan and S. Rastogi, “Surgery in Ewing’s Sarcoma-Myth or Reality,” Indian Journal of Medical Pediatric Oncology, Vol. 25, No. 2, 2004, pp. 58-63. doi:10.1097/BLO.0b013e318059b8c9
[10] T. A. Damron, W. G. Ward and A. Stewart, “Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma: National Cancer Data Base Report,” Clinical Orthopaedics and Related Research, Vol. 459, 2007, pp. 40-47.
[11] S. Bhagat, H. Sharma, D. S. Pillai and M. J. Jane, “Pelvic Ewing’s Sarcoma: A Review from Scottish Bone Tumour Registry,” The Journal of Orthopaedic Surgery, Vol. 16, No. 3, 2008, pp. 333-338.
[12] A. Puri, A. Gulia, N. A. Jambhekar and S. Laskar, “Results of Surgical Resection in Pelvic Ewing’s Sarcoma,” Journal of Surgical Oncology, Vol. 106, No. 4, 2012, pp. 417-422.
[13] G. Rosen, N. Wollner, C. Tan, et al., “Proceedings: Disease-Free Survival in Children with Ewing’s Sarcoma Treated with Radiation Therapy and Adjuvant Four-Drug Sequential Chemotherapy,” Cancer, Vol. 33, No. 2, 1974, pp. 384-393. doi:10.1002/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T
[14] H. E. Grier, M. D. Krailo and N. J. Tarbell, “Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone,” The New England Journal of Medicine, Vol. 348, 2003, pp. 694-701. doi:10.1056/NEJMoa020890
[15] S. Ferrari, E. Palmerini, M. Alberghini, et al., “Vincristine, Doxorubicin, Cyclophosfamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study,” Tumori, Vol. 96, No. 2, 2010, pp. 213-218.
[16] M. Paulussen, S. Bielack, H. Jurgens and P. G. Casali, “Ewing’s Sarcoma of the Bone: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 20, No. 4, 2009, pp. 140-142. doi:10.1093/annonc/mdn103
[17] R. B. Womer, D. C. West, M. D. Krailo, P. S. Dickman and B. Pawel, “Randomized Comparison of Every-Two-Week vs. Every-Three-Week Chemotherapy in Ewing Sarcoma Family Tumors (ESFT),” Journal of Clinical Oncology, Vol. 26, No. 20, 2008, pp. 504-512.
[18] C. Rodriguez-Galindo, T. Liu, M. J. Krasin, et al., “Analysis of Prognostic Factors in Ewing Sarcoma Family of Tumors: Review of St. Jude Children’s Research Hospital Studies,” Cancer, Vol. 110, No. 2, 2007, pp. 375-384. doi:10.1002/cncr.22821
[19] G. Bacci, A. Longhi, S. Ferrari, M. Mercuri, M. Versari and F. Bertoni, “Prognostic Factors in Non-Metastatic Ewing’s Sarcoma Tumor of Bone: An Analysis of 579 Patients Treated at a Single Institution with Adjuvant or Neoadjuvant Chemotherapy between 1972 and 1998,” Acta Oncologica, Vol. 45, No. 4, 2006, pp. 469-475. doi:10.1080/02841860500519760
[20] J. A. Lee, D. H. Kim, J. B. Cho, et al., “Treatment Outcome of Korean Patients with Localized Ewing Sarcoma Family of Tumors: A Single Institution Experience,” Japanese Journal of Clinical Oncology, Vol. 41, No. 6, 2011, pp. 776-782. doi:10.1093/jjco/hyr033
[21] G. C. Rodriguez, F. Navid, T. Liu, C. A. Billups, B. N. Rao and M. J. Krasin, “Prognostic Factors for Local and Distant Control in Ewing Sarcoma Family of Tumors,” Annals of Oncology, Vol. 19, No. 4, 2008, pp. 814-820. doi:10.1093/annonc/mdm521
[22] B. M. Seddon and J. S. Whelan, “Emerging Chemotherapeutic Strategies and the Role of Treatment Stratification in Ewing Sarcoma,” Pediatr Drugs, Vol. 10, No. 2, 2008, pp. 93-105. doi:10.2165/00148581-200810020-00004
[23] J. Lee, B. H. Hoang, A. Ziogas and J. A. Zell, “Analysis of Prognostic Factors in Ewing Sarcoma Using a Population-Based Cancer Registry,” Cancer, Vol. 116, No. 8, 2010, pp. 1964-1973. doi:10.1002/cncr.24937
[24] G. Bacci, A. Longhi, F. Fagioli, A. Briccoli, M. Versari and P. Picci, “Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities: 27 Year Experience at Rizzoli Institute, Italy,” European Journal of Cancer, Vol. 41, No. 18, 2005, pp. 2836-2845. doi:10.1016/j.ejca.2005.08.026
[25] P. M. Simpson, R. Reid and D. Porter, “Ewing’s Sarcoma of the Upper Extremity: Presenting Symptoms, Diagnostic Delay and Outcome,” Sarcoma, Vol. 9, No. 1-2, 2005, pp. 15-20. doi:10.1080/00207540500050113
[26] S. J. Cotterill, S. Ahrens, M. Paulussen, et al., “Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group,” Journal of Clinical Oncology, Vol. 18, No. 17, 2000, pp. 3108-3114.
[27] F. Fiorenza and L. Jeys, “Ewing’s Sarcoma of Bone-Mini-Symposium,” Journal of Orthopaedic Trauma, Vol. 24, No. 5, 2010, pp. 342-345.
[28] G. Bacci, S. Ferrari, F. Bertoni, et al., “Prognostic Factors in Nonmetastatic Ewing’s Sarcoma of Bone Treated with Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli,” Journal of Clinical Oncology, Vol. 18, No. 1, 2000, pp. 4-11.
[29] V. Subbiah, P. Anderson, A. J. Lazar, E. Burdett, K. Raymond and J. A. Ludwig, “Ewing’s Sarcoma: Standard and Exterimental Treatment Options,” Current Treatment Options in Oncology, Vol. 10, No. 1-2, 2009, pp. 126-140. doi:10.1007/s11864-009-0104-6
[30] L. M. Barker, T. W. Pendergrass, J. E. Sanders and D. S. Hawkins, “Survival after Recurrence of Ewing’s Sarcoma Family of Tumors,” Journal of Clinical Oncology, Vol. 23, No. 19, 2005, pp. 4354-4362.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.